Rockwell Medical (NASDAQ:RMTI) Issues Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.20, FiscalAI reports. The business had revenue of $17.78 million for the quarter, compared to the consensus estimate of $17.82 million. Rockwell Medical had a negative net margin of 7.98% and a negative return on equity of 15.41%.

Here are the key takeaways from Rockwell Medical’s conference call:

• Second-quarter net sales rose 11% year over year to $17.8 million, driven by new Western U.S. customers, higher purchasing from existing customers, and pricing actions. Management said it remains on track for 2026 sales guidance of $70 million to $75 million.
• Gross margin expanded to 18% from 16% a year ago, while gross profit increased 30% to $3.2 million. The company attributed the improvement to lower manufacturing costs, automation, higher volumes, and operational efficiencies, and reiterated its full-year gross-margin target of 18% to 22%.
• Rockwell generated approximately $2.1 million in operating cash flow during the quarter and ended June with $24.8 million in cash and available-for-sale investments. Management reiterated expectations for positive operating cash flow and adjusted EBITDA of $1 million to $2 million in 2026.
• Expansion in the Western U.S. is gaining traction, with incremental volume carrying margins above the company average and liquid products representing a larger share of the regional mix. New and renewed customer agreements, generally structured for about three years with pricing escalators, are also increasing revenue visibility.
• The company is evaluating a complementary renal-care medical device that could address a sizable market and potentially face limited U.S. competition. Development remains early-stage, with investment funded from the existing balance sheet and no additional capital raise currently planned.

Rockwell Medical Stock Up 4.1%

RMTI stock traded up $0.31 during trading hours on Thursday, reaching $7.82. 81,208 shares of the stock were exchanged, compared to its average volume of 32,157. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.74 and a quick ratio of 3.43. The company has a market cap of $31.05 million, a price-to-earnings ratio of -5.21 and a beta of 1.60. Rockwell Medical has a 12 month low of $4.89 and a 12 month high of $21.00. The firm’s 50-day moving average is $6.46 and its 200-day moving average is $8.23.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RMTI shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective (up from $2.00) on shares of Rockwell Medical in a report on Thursday, July 9th. Wall Street Zen raised shares of Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. Finally, Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.00.

Institutional Trading of Rockwell Medical

A number of large investors have recently added to or reduced their stakes in RMTI. Vanguard Group Inc. grew its position in shares of Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Jane Street Group LLC acquired a new position in Rockwell Medical in the fourth quarter valued at about $84,000. XTX Topco Ltd increased its holdings in Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after buying an additional 46,029 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after purchasing an additional 41,668 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.